Literature DB >> 18983438

Hyperzincemia and hypercalprotectinemia: unsuccessful treatment with tacrolimus.

B Isidor1, S Poignant, N Corradini, M Fouassier, P Quartier, J Roth, G Picherot.   

Abstract

UNLABELLED: We report on a 5-year-old boy with hyperzincemia and hypercalprotectinemia. Treatment began with Tacrolimus at the age of 4 years and 6 months. Despite an initial correction of clinical and biological symptoms, zincemia and calprotectinemia progressively worsened with secondary reappearance of symptoms.
CONCLUSION: Tacrolimus seems to have a transient effect in the treatment of Hyperzincemia and hyperprolactinemia.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18983438     DOI： 10.1111/j.1651-2227.2008.01092.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN： 0803-5253            Impact factor:   2.299


  5 in total

Review 1.  Nutritional Immunity: S100 Proteins at the Host-Pathogen Interface.

Authors:  Joseph P Zackular; Walter J Chazin; Eric P Skaar
Journal:  J Biol Chem       Date:  2015-06-08       Impact factor: 5.157

Review 2.  Nutritional immunity: transition metals at the pathogen-host interface.

Authors:  M Indriati Hood; Eric P Skaar
Journal:  Nat Rev Microbiol       Date:  2012-07-16       Impact factor: 60.633

Review 3.  The role of calprotectin in pediatric disease.

Authors:  George Vaos; Ioannis D Kostakis; Nick Zavras; Athanasios Chatzemichael
Journal:  Biomed Res Int       Date:  2013-09-23       Impact factor: 3.411

Review 4.  PSTPIP1-associated myeloid-related proteinaemia inflammatory (PAMI) syndrome; a case presenting as a perinatal event with early central nervous system involvement?

Authors:  Bethany Gillies Whiteside; Hannah Titheradge; Eslam Al-Abadi
Journal:  Pediatr Rheumatol Online J       Date:  2022-07-15       Impact factor: 3.413

Review 5.  S100 Proteins As an Important Regulator of Macrophage Inflammation.

Authors:  Chang Xia; Zachary Braunstein; Amelia C Toomey; Jixin Zhong; Xiaoquan Rao
Journal:  Front Immunol       Date:  2018-01-05       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.